Accord Healthcare Polska SP. Z.o.o. Pharmaceutical Import Profile — Poland (DGFT 2022–2026)

Name: Accord Healthcare Polska SP. Z.o.o. Pharmaceutical Import Records from India — 8 Products, $5.8M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Accord Healthcare Polska SP. Z.o.o. — Pharmaceutical Importer Profile (2026) | 8 Products, $5.8M Trade | TransData Nexus

Accord Healthcare Polska SP. Z.o.o.

Pharmaceutical Importer · Poland · Oncology Focus · $5.8M Total Trade · DGFT Verified

Accord Healthcare Polska SP. Z.o.o. is a pharmaceutical importer based in Poland with a total trade value of $5.8M across 8 products in 2 therapeutic categories. Based on 252 verified import shipments from Indian Customs (DGFT) records, Accord Healthcare Polska SP. Z.o.o. is the #1 buyer in 1 product including Cabazitaxel. Accord Healthcare Polska SP. Z.o.o. sources from 1 verified Indian supplier, with Intas Pharmaceuticals Limited accounting for 100.0% of imports.

Accord Healthcare Polska SP. Z.o.o. — Import Portfolio & Supplier Network

Accord Healthcare Polska SP. Z.o.o. import network — 8 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Accord Healthcare Polska SP. Z.o.o.?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Intas Pharmaceuticals Limited	$1.8M	126	100.0%

Accord Healthcare Polska SP. Z.o.o. sources from 1 verified Indian supplier across 82 distinct formulations. The sourcing is highly concentrated — Intas Pharmaceuticals Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
Pharma drugs & medi:pelgraz 6MG/0.6ML	$200.0K	4
Pharma drugs & medi:vinorelbine INJ,10MG	$96.3K	3
Pharma drug&med:icatibant pfs	$91.6K	2
Pharma drug&med:pregabalin 75MG	$70.9K	2
Pharma drug&med:cinacalcet hcl 30MG	$52.1K	2
Pharma drug&med:irinotecan INJ,20MG/ML	$50.0K	1
Pharma drugs & medi: accofil 48mu/0.5ML	$50.0K	1
Pharma drugs & medi: zercepac 150MG 1vial(ro) 3131x1x1	$50.0K	1
Pharma drugs & medi:zercepac 150MG 1vial(bg) 838x1x1 vial as per	$50.0K	1
Pharma drugs & medi:zercepac 150MG 1vial(czpl) 1641x1x1 vial as per	$50.0K	1
Pharma drugs & medi: fludarabinephoinj25mg/ml2mlx1v (aco-polan 2705x1x1vial as per	$50.0K	1
Pharma drugs & medi: pelgraz 6MG/0.6ML 1pfs(hu)ima_n 2555x1x1	$50.0K	1
Pharma drug&med:cytarabine INJ,100MG/ML	$46.6K	3
Pharma drug&med:clopizam(cloza)100MG	$44.9K	1
Pharma drugs & medi: pelgraz 6MG/0.6ML	$42.9K	1

Import Portfolio — Top 8 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Irinotecan	Oncology	$3.3M	131	1.4%	14
2	Topotecan	Advanced Oncology	$923.7K	50	1.2%	16
3	Fludarabine	Advanced Oncology	$472.3K	18	3.1%	8
4	Vinorelbine	Advanced Oncology	$428.9K	21	6.1%	4
5	Fulvestrant	Advanced Oncology	$300.0K	6	2.1%	12
6	Cabazitaxel	Advanced Oncology	$200.0K	4	1.1%	1
7	Etoposide	Oncology	$134.6K	20	1.2%	14
8	Busulfan	Advanced Oncology	$100.0K	2	2.0%	5

Accord Healthcare Polska SP. Z.o.o. imports 8 pharmaceutical products across 2 categories into Poland totaling $5.8M. The company is the #1 buyer for 1 product: Cabazitaxel.

Accord Healthcare Polska SP. Z.o.o. — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Accord Healthcare Polska Sp. z o.o. is the Polish subsidiary of Accord Healthcare, an international pharmaceutical group specializing in generic, biosimilar, and value-added medicines. Established in 2011, the company is headquartered at Ul. Taśmowa 7, 02-677 Warsaw, Poland. Accord Healthcare Polska is integrated into Accord's European manufacturing and R&D platform, coordinating deliveries for the domestic market and selected Central and Eastern European and export markets, including through public tenders and hospital procurement programs.

The company develops, registers, markets, and distributes a broad portfolio of prescription medicines for hospitals, retail pharmacies, and wholesalers in Poland. Its product range covers numerous therapeutic classes, with particular strength in oncology medicines, as well as cardiovascular, central nervous system, anti-infective, and other key therapy areas, offered in injectable, oral solid, and other dosage forms.

2Distribution Network

Accord Healthcare Polska operates as a commercial and distribution hub integrated into Accord's European manufacturing and R&D platform. The company coordinates deliveries for the domestic market and selected Central and Eastern European and export markets, including through public tenders and hospital procurement programs. While specific warehouse locations and logistics capabilities are not publicly disclosed, the company's integration into Accord's European network suggests a robust distribution infrastructure capable of serving both domestic and regional markets.

3Industry Role

Accord Healthcare Polska Sp. z o.o. functions as a pharmaceutical importer and distributor within Poland's supply chain. The company imports finished pharmaceutical formulations from various suppliers, including a significant volume from India, and distributes these products to hospitals, retail pharmacies, and wholesalers across Poland. This role positions Accord Healthcare Polska as a key player in ensuring the availability of essential medicines within the Polish healthcare system.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Accord Healthcare Polska SP. Z.o.o.

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Accord Healthcare Polska's sourcing strategy exhibits a high degree of concentration, with a total import value from India amounting to $5.8 million USD across 252 shipments, primarily from a single supplier, INTAS Pharmaceuticals Limited. This single-source dependency may pose risks related to supply chain disruptions, pricing fluctuations, and potential regulatory changes affecting the supplier. However, the consistent volume of shipments suggests a stable and long-term relationship between Accord Healthcare Polska and INTAS Pharmaceuticals Limited, indicating mutual trust and reliability.

The shipment data reveals that Accord Healthcare Polska imports a diverse range of formulations, with a total of 82 unique formulations. This diversity indicates a strategic approach to sourcing, aiming to meet various therapeutic needs and mitigate risks associated with over-reliance on a single product or formulation. Nonetheless, the heavy reliance on a single supplier underscores the importance of maintaining a robust and resilient supply chain to ensure uninterrupted access to critical medicines.

2Supply Chain Resilience

Accord Healthcare Polska's supply chain resilience is closely tied to its relationship with INTAS Pharmaceuticals Limited, the primary supplier of finished pharmaceutical formulations from India. The company's import data indicates a significant volume of shipments from this supplier, suggesting a strong and dependable partnership. However, the lack of publicly available information regarding backup suppliers and the specific formulations imported limits the assessment of the supply chain's overall resilience. To enhance resilience, it would be prudent for Accord Healthcare Polska to diversify its supplier base and establish contingency plans to mitigate potential disruptions.

Importing Pharmaceuticals into Poland — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Poland

1Regulatory Authority & Framework

In Poland, the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products (URPL) is the primary regulatory authority overseeing pharmaceutical imports. The key legislation governing pharmaceutical imports includes the Pharmaceutical Law Act and the Act on Medical Devices, which establish the regulatory framework for the registration, importation, and distribution of medicinal products. The marketing authorization pathway for Indian generics involves obtaining a marketing authorization from the URPL, which may include procedures such as the Mutual Recognition Procedure (MRP) or the Decentralized Procedure (DCP), depending on the product's characteristics and the markets involved.

2Import Licensing & GMP

Import licensing requirements in Poland stipulate that all medicinal products imported into the country must be authorized by the URPL. Indian exporters seeking to supply Accord Healthcare Polska must ensure that their products are manufactured in facilities holding valid Good Manufacturing Practice (GMP) certificates recognized by the European Union, such as EU GMP, WHO GMP, or PIC/S certifications. Additionally, Indian exporters must obtain wholesale distribution authorization from the URPL to legally distribute their products within Poland.

Quality & Labeling

Accord Healthcare Polska SP. Z.o.o. — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Accord Healthcare Polska's product strategy focuses on therapeutic areas with high unmet medical needs, particularly oncology, immunosuppressants, central nervous system disorders, and rheumatology. The company's imports from India align with these strategic priorities, emphasizing the need for cost-effective, high-quality medicines in these critical areas. Market demand for these products is driven by the prevalence of related diseases and the necessity for accessible treatment options within the Polish healthcare system.

2Sourcing Profile

Accord Healthcare Polska's sourcing strategy emphasizes the procurement of generic drugs, with a preference for formulations that address significant therapeutic needs. India's role as a supplier is integral to this strategy, given its capacity to provide a diverse range of high-quality, cost-effective pharmaceutical products. The company's focus on finished pharmaceutical formulations, rather than raw APIs or bulk drugs, indicates a preference for ready-to-market products that can be swiftly integrated into the Polish market.

3Market Positioning

Seller's Guide — How to Become a Supplier to Accord Healthcare Polska SP. Z.o.o.

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter Accord Healthcare Polska's supply chain, particularly if they can offer high-quality, cost-effective products in therapeutic areas of strategic importance to the company. Gaps in Accord Healthcare Polska's current sourcing may exist in specific formulations or dosage forms not currently covered by existing suppliers. Indian exporters can assess these opportunities by analyzing the company's product portfolio and identifying areas where their offerings can add value.

2Requirements & Qualifications

Indian exporters seeking to supply Accord Healthcare Polska and the Polish market must ensure that their manufacturing facilities hold valid GMP certifications recognized by the European Union, such as EU GMP, WHO GMP, or PIC/S. Products must comply with Polish regulatory requirements, including appropriate labeling in the Polish language and adherence to serialization mandates. Additionally, exporters must obtain wholesale distribution authorization from the URPL to legally distribute their products within Poland.

3How to Approach

Frequently Asked Questions — Accord Healthcare Polska SP. Z.o.o.

What products does Accord Healthcare Polska SP. Z.o.o. import from India?

Accord Healthcare Polska SP. Z.o.o. imports 8 pharmaceutical products across 2 categories. Top imports: Irinotecan ($3.3M), Topotecan ($923.7K), Fludarabine ($472.3K), Vinorelbine ($428.9K), Fulvestrant ($300.0K).

Who supplies pharmaceuticals to Accord Healthcare Polska SP. Z.o.o. from India?

Accord Healthcare Polska SP. Z.o.o. sources from 1 verified Indian suppliers. The primary supplier is Intas Pharmaceuticals Limited (100.0% of imports, $1.8M).

What is Accord Healthcare Polska SP. Z.o.o.'s total pharmaceutical import value?

Accord Healthcare Polska SP. Z.o.o.'s total pharmaceutical import value from India is $5.8M, based on 252 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Accord Healthcare Polska SP. Z.o.o. focus on?

Accord Healthcare Polska SP. Z.o.o. imports across 2 categories. The largest: Oncology (58.5%), Advanced Oncology (41.5%).

Get Full Accord Healthcare Polska SP. Z.o.o. Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 5 company name variants from customs records. For current shipment-level data, contact TransData Nexus.